Mattson Financial Services LLC Invests $1.13 Million in Becton, Dickinson and Company (NYSE:BDX)

Mattson Financial Services LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, HoldingsChannel reports. The fund bought 4,845 shares of the medical instruments supplier’s stock, valued at approximately $1,132,000.

Other large investors have also recently made changes to their positions in the company. Jennison Associates LLC boosted its position in shares of Becton, Dickinson and Company by 4.9% in the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after purchasing an additional 18,786 shares during the period. Norden Group LLC raised its stake in Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after acquiring an additional 49,559 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new stake in Becton, Dickinson and Company during the 1st quarter valued at approximately $11,998,000. Avity Investment Management Inc. raised its stake in Becton, Dickinson and Company by 3.5% during the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after acquiring an additional 5,527 shares during the last quarter. Finally, Caden Capital Partners LP raised its stake in Becton, Dickinson and Company by 26.7% during the 4th quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock valued at $20,340,000 after acquiring an additional 17,599 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $239.76 on Thursday. The business’s fifty day moving average price is $236.55 and its two-hundred day moving average price is $235.57. The stock has a market cap of $69.29 billion, a PE ratio of 52.81, a price-to-earnings-growth ratio of 1.92 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same quarter last year, the firm earned $2.96 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. On average, analysts forecast that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.58%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of analyst reports. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Raymond James cut their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the stock from $255.00 to $275.00 in a research note on Tuesday. Stifel Nicolaus increased their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.